Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rocket Pharmaceuticals (RCKT) Goodwill (2018 - 2025)

Rocket Pharmaceuticals (RCKT) has disclosed Goodwill for 8 consecutive years, with $39.2 million as the latest value for Q4 2025.

  • Quarterly Goodwill changed 0.0% to $39.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $39.2 million through Dec 2025, changed 0.0% year-over-year, with the annual reading at $39.2 million for FY2025, 0.0% changed from the prior year.
  • Goodwill hit $39.2 million in Q4 2025 for Rocket Pharmaceuticals, roughly flat from $39.2 million in the prior quarter.
  • In the past five years, Goodwill ranged from a high of $39.2 million in Q4 2022 to a low of $30.8 million in Q1 2021.
  • Historically, Goodwill has averaged $36.3 million across 5 years, with a median of $39.2 million in 2023.
  • Biggest five-year swings in Goodwill: grew 27.21% in 2022 and later dropped 0.12% in 2023.
  • Year by year, Goodwill stood at $30.8 million in 2021, then grew by 27.21% to $39.2 million in 2022, then fell by 0.12% to $39.2 million in 2023, then grew by 0.12% to $39.2 million in 2024, then changed by 0.0% to $39.2 million in 2025.
  • Business Quant data shows Goodwill for RCKT at $39.2 million in Q4 2025, $39.2 million in Q3 2025, and $39.2 million in Q2 2025.